TABLE 8

Mean (±SE) neuroglycopenic symptom scores during hyperinsulinemic stepped hypoglycemic clamps on the morning and, after an additional 2 h of hypoglycemia (50 mg/dl), the afternoon of day 1 and on the morning of day 2 in nondiabetic subjects (n = 15) and patients with type 2 diabetes treated with OHA (n = 7) or insulin (n = 6)

Time (min)
P
−30−150306090120150180210240270300
Nondiabetic subjects
 Day 12.5 ± 0.52.3 ± 0.52.6 ± 0.62.5 ± 0.72.7 ± 0.52.7 ± 0.53.3 ± 0.83.4 ± 0.83.4 ± 0.73.5 ± 0.95.2 ± 1.48.5 ± 1.712.4 ±
 Day 22.2 ± 0.52.2 ± 0.72.5 ± 0.62.4 ± 0.72.3 ± 0.72.5 ± 0.72.7 ± 0.72.9 ± 0.93.6 ± 1.04.3 ± 1.15.6 ± 1.16.7 ± 1.29.4 ± 1.20.0467
Type 2 diabetic patients
 OHA Rx*
  Day 13.3 ± 0.83.0 ± 0.62.3 ± 0.64.7 ± 2.01.0 ± 0.51.3 ± 0.72.7 ± 1.46.7 ± 3.28.0 ± 2.411.1 ± 3.317.6 ± 5.218.1 ± 3.621.7 ± 4.0
  Day 20.7 ± 0.51.0 ± 0.61.3 ± 0.81.0 ± 0.50.3 ± 0.20.8 ± 0.60.8 ± 0.51.0 ± 0.72.0 ± 0.93.7 ± 1.55.3 ± 1.48.7 ± 2.411.0 ± 2.90.0097
Insulin Rx
  Day 11.5 ± 0.61.3 ± 0.22.0 ± 1.52.8 ± 1.21.8 ± 0.62.7 ± 0.92.2 ± 0.82.5 ± 0.82.3 ± 0.62.7 ± 0.810.8 ± 3.39.5 ± 3.118.5 ± 4.7
  Day 21.3 ± 0.71.3 ± 0.90.8 ± 0.61.0 ± 0.61.0 ± 0.61.2 ± 0.61.0 ± 0.61.0 ± 0.61.2 ± 0.72.0 ± 0.64.8 ± 1.88.4 ± 5.76.6 ± 1.40.0082
  • *

    * Type 2 diabetic (n = 13) P = 0.0015 day 2 versus day 1;

  • **

    ** day 1 P = 0.0182 versus nondiabetic.